New study examines real-world switching patterns after patients transition from Humira to biosimilars

Analysis of nearly 68,000 patients finds biosimilar adoption increased following formulary changes; however, more than 1 in 7 patients switch back to HumiraBELLEVUE, Wash., June 29, 2026 (GLOBE ...

AbbVie broadens immunology focus with $10.9 billion Apogee deal

Seeking to replace blockbuster drugs that will soon lose patent protection, drug-maker AbbVie purchased a biotech firm for ...

Big Pharma's Looming Patent Cliff Period And How It Is Trying To Address It

Big pharma’s patent cliff may be overstated: layered IP, incremental innovation, and smart licensing extend exclusivity and ...

3 no-brainer dividend stocks to buy right now

AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.
Zacks Investment Research on MSN

ABBV gets CHMP nod for Rinvoq in two different autoimmune diseases

AbbVie ABBV announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...